Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProVIVA-SA-1: Safety and Immunogenicity of hAd5-S-Fusion+N-ETSD COVID-19 Vaccine in Healthy South African Adults
NCT04710303Phase 1Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Mar 2021
- Primary completion
- Aug 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of hAd5-S-Fusion + N-ETSD in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by ImmunityBio, Inc. Primary endpoints: Medically Attended Adverse Events at 6 months, Solicited Local Reactogenicity AEs at 29 days and 2 more. Started Mar 2021; status: completed.
02
Drugs
hAd5-S-Fusion + N-ETSD
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04710303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04710303.